You are now leaving GSK’s website

You are now leaving a GSK Website. By clicking this link, you will be taken to a website that is not owned or controlled by GSK, and GSK is not responsible for the content provided on that site

Continue

Go back

Risk factors for psychiatric and behavioural side effects (PBSEs) associated with anti-epileptic drug (AED) use.

PBSEs are a well-recognised complication in patients taking AEDs.1,2 In one review, overall, 16% of patients taking 2nd generation AEDs experienced PBSEs (mean duration of treatment ranged from 6–19 months).2

Understanding the increased risk of PBSEs with AEDs might help clinicians and patients with their treatment choice.

In a recent retrospective open-cohort study among 1173 patients with epilepsy receiving levetiracetam, a total of 14.1% experienced a psychiatric symptom or disorder within two years of the index prescription.3 Risk factors underlying these PBSEs were determined.3

*Multivariable logistic regression

Read more about Keppra

Abbreviations

AED: anti-epileptic drug; PBSE: psychiatric and behavioural side effect.

References

  1. Brodie M, et al. Pharmacol Rev 2016;68:563–602.
  2. Weintraub D, et al. Epilepsy Behav 2007;10:105–110.
  3. Josephson CB, et al. JAMA Neurol 2019;76(4):440–446.

 

GSK shall not be liable for any damages, claims, liabilities, costs or obligations arising from the use or misuse of information provided herein. 
For safety information on GSK products or to report an Adverse Event, please contact the toll free line 
0800 CALL GSK (0800 2255 475) or email aereporting.ng@gsk.com 
Full prescribing information is available on request on www.gskpro.com
Please note that it may take up to 10 days to process your request. If you need further assistance contact 
GSK House, 1 Industrial Avenue llupeju, Lagos or via email at customercare_ph_nigeria@gsk.com
GlaxoSmithKline Pharmaceutical Nigeria Ltd, 1 Industrial Avenue, llupeju, Lagos 234-1-271 1000 
©2020 GSK group of companies or its licensor 
Trade marks are owned by or licensed to the GSK group of companies

®Keppra is a registered trademark owned by UCB licensed to GSK group of companies.

PM-NG-LVT-WCNT-200004 Date of preparation: November 2020.